SynthesisPloS one2016
Anti-Tumor Effects of Ketogenic Diets in Mice: A Meta-Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05119010 (A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma), which is not on this map. Cited by 70 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Who cites it
70 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The use of ketogenic diets in cancer patients: a systematic review.Clinical and experimental medicine · 2021Pooled it
- Cancer Treatment With the Ketogenic Diet: A Systematic Review and Meta-analysis of Animal Studies.Frontiers in nutrition · 2021Pooled it
- Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes.Medical oncology (Northwood, London, England) · 2020Pooled it
- The role of ketogenic diets in the therapeutic management of adult and paediatric gliomas: a systematic review.CNS oncology · 2018Pooled it
- Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation.Medical oncology (Northwood, London, England) · 2026Review
- Review
- Sex-Specific Determinants of the Ketone Body β-Hydroxybutyrate in the General Population.The Journal of clinical endocrinology and metabolism · 2026Article
- The Ketogenic Diet Through a Metabolomic Lens: Biochemical Pathways, Therapeutic Applications, and Analytical Challenges.Nutrients · 2025Review
- Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.Clinical epigenetics · 2025Review
- Rethinking corticosteroids use in oncology.Frontiers in pharmacology · 2025Article
- Review
- Ketogenic diet does not promote triple-negative and luminal mammary tumor growth and metastasis in experimental mice.Clinical & experimental metastasis · 2024Article
- Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy.Cancer research · 2024Article
- Review
- The combined treatment with ketogenic diet and metformin slows tumor growth in two mouse models of triple negative breast cancer.Translational medicine communications · 2024Article
- Beta-Hydroxybutyrate: A Supplemental Molecule for Various Diseases.Current drug targets · 2024Review
- The Combined Treatment with Ketogenic Diet and Metformin Slows Tumor Growth in Two Mouse Models of Triple Negative Breast Cancer.Research square · 2023Article
- Long-Term Effects of a Ketogenic Diet for Cancer.Nutrients · 2023Article
- Mitochondrial complex III deficiency drives c-MYC overexpression and illicit cell cycle entry leading to senescence and segmental progeria.Nature communications · 2023Article
- Ketogenic therapies for glioblastoma: Understanding the limitations in transitioning from mice to patients.Frontiers in nutrition · 2023Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently ketogenic diets (KDs) are hyped as an anti-tumor intervention aimed at exploiting the metabolic abnormalities of cancer cells. However, while data in humans is sparse, translation of murine tumor models to the clinic is further hampered by small sample sizes, heterogeneous settings and mixed results concerning tumor growth retardation. The aim was therefore to synthesize the evidence for a growth inhibiting effect of KDs when used as a monotherapy in mice.
methodsWe conducted a Bayesian random effects meta-analysis on all studies assessing the survival (defined as the time to reach a pre-defined endpoint such as tumor volume) of mice on an unrestricted KD compared to a high carbohydrate standard diet (SD). For 12 studies meeting the inclusion criteria either a mean survival time ratio (MR) or hazard ratio (HR) between the KD and SD groups could be obtained. The posterior estimates for the MR and HR averaged over four priors on the between-study heterogeneity τ2 were MR = 0.85 (95% highest posterior density interval (HPDI) = [0.73, 0.97]) and HR = 0.55 (95% HPDI = [0.26, 0.87]), indicating a significant overall benefit of the KD in terms of prolonged mean survival times and reduced hazard rate. All studies that used a brain tumor model also chose a late starting point for the KD (at least one day after tumor initiation) which accounted for 26% of the heterogeneity. In this subgroup the KD was less effective (MR = 0.89, 95% HPDI = [0.76, 1.04]).
conclusionsThere was an overall tumor growth delaying effect of unrestricted KDs in mice. Future experiments should aim at differentiating the effects of KD timing versus tumor location, since external evidence is currently consistent with an influence of both of these factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.